FOI 5684

**Please note we do not have records and/or search capabilities to be able to identify all these requests or treatments. The answers below are to the best of our knowledge based partly on staff memories and then specific searches for the occurrences remembered.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **FY**  **14-15** | **15-16** | **16-17** | **17-18** | **18-19** | **19-20** | **20-21** | **21-22** | **22-23** | **April 23 (up to 21/4/23)** |
| 1. Patients supplied medicines via EAMS |  |  |  |  |  |  |  | 4 | 5 | 5 |
| 2. Requests made for company-led compassionate use or FOC schemes |  |  |  |  |  | 36 |  | 1 | 4 |  |
| 2a. Patients treated with unlicensed meds obtained via 2. \* |  |  |  |  |  |  |  |  | 1 |  |
| 3. Requests submitted for access to unlicensed medicines outside of company-led scheme. \* |  |  |  |  |  |  |  |  |  | 1 |
| 3a. Patients receiving unlicensed medicines obtained via 3. |  |  |  |  |  |  |  |  |  |  |

\***2a figures are for unlicensed medicines, rather than licensed medicines used for an unlicensed indication**

**\*3 figure are for unlicensed medicines otherwise unavailable where specific requests have to be made, eg pre-licensing, rather than eg unlicensed medicines imported from abroad.**